News
Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...
The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...
U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered ...
A new executive order aims to smooth the path for getting U.S. manufacturing facilities up and running; HHS says it will ...
Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...
Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) ...
Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...
Zepbound, Lilly’s obesity drug, has overtaken Novo’s equivalent, Wegovy, in the US and now commands over 50 per cent of the ...
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...
The summary highlights significant updates in the health sector, including Glenview Capital reducing its CVS stake, WeightWatchers' filing for bankruptcy, FDA's bargaining session cancellations, Novo ...
CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback